SPY—
QQQ—
DIA—
NVDA—
AAPL—
TSLA—
MSFT—
BTC-USD—
15-min delayed
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Vertex Pharmaceuticals Inc

VRTX XNAS
$515.02 -5.64 (-1.08%) ▼ 15-min delayed
Open
$529.94
High
$531.37
Low
$513.80
Volume
1.77M
Market Cap
$132.01B

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 6.4K Website →

Earnings & Analyst Ratings

Next Earnings: Wed, Feb 10, 2027
Calendar →

Get VRTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Vertex Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.